Development and Testing of Novel Interventions to Improve HIV Prevention, Treatment, and Program Implementation for People Who Use Substances (R34 Clinical Trial Required)
ID: 358093Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/358093

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-24-329.html
Timeline
  1. 1
    Forecast Posted Not available
  2. 2
    Forecast Due Not available
  3. 3
    Posted Jan 8, 2025, 12:00 AM UTC
  4. 4
    Due May 7, 2027, 12:00 AM UTC
Description

The National Institutes of Health (NIH) is offering a funding opportunity titled "Development and Testing of Novel Interventions to Improve HIV Prevention, Treatment, and Program Implementation for People Who Use Substances" under the R34 planning grant mechanism. This initiative aims to encourage formative research and the development of innovative interventions that target HIV prevention and care, particularly for populations that engage in substance use, addressing critical gaps in HIV care and prevention. Eligible applicants include a wide range of organizations such as higher education institutions, nonprofit entities, and tribal governments, with grants available for up to $450,000 over three years. The application cycle begins on April 7, 2025, with subsequent due dates throughout the year, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.

Point(s) of Contact
grantsinfo@nih.gov
Files
Title
Posted
PAR-24-329-Full-Announcement.html
Jan 10, 2025, 12:05 PM UTC
PAR-24-329.html
Jan 10, 2025, 12:05 PM UTC
The Department of Health and Human Services, through the National Institutes of Health (NIH), is issuing a funding opportunity titled "Development & Testing of Novel Interventions to Improve HIV Prevention, Treatment, and Program Implementation for People Who Use Substances" under the R34 planning grant mechanism. This initiative encourages research that develops and tests innovative interventions targeting HIV prevention and care, particularly for populations that engage in substance use. The funding aims to address critical gaps in HIV care and prevention, including integration with substance use disorder treatments and improving the reach of interventions. Eligible organizations include higher education institutions and nonprofit entities, with grants offering up to $450,000 for three years. Applications must include a "Plan for Enhancing Diverse Perspectives," focusing on inclusivity in research. The application cycle starts on April 7, 2025, with subsequent due dates throughout the year. The NIH emphasizes the need for pilot studies addressing the complex relationship between substance use and HIV, aiming for scalable and sustainable solutions. The program underscores a collaborative approach, involving community stakeholders and end users to enhance the efficacy and accessibility of interventions.
Similar Opportunities
High Priority HIV and Substance Use Research (RM1 Clinical Trial Optional)
National Institutes of Health
The National Institutes of Health (NIH) is offering a funding opportunity titled "High Priority HIV and Substance Use Research (RM1 Clinical Trial Optional)" aimed at supporting innovative research that addresses the intersection of HIV and substance use. This initiative invites applications from individual researchers and research teams to develop projects that can lead to new prevention, treatment, and care strategies for individuals affected by both conditions, with a requirement for a detailed research plan and preliminary data. A total budget of $3.0 million is available for funding one to two awards, with individual project budgets capped at $1.5 million per fiscal year, and applications are due by February 12, 2027. Interested applicants can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries and are encouraged to consult with NIDA program staff early in the application process.
Formative and Pilot Intervention Research to Optimize HIV Prevention and Care Continuum Outcomes (R34 Clinical Trial Optional)
National Institutes of Health
The National Institutes of Health (NIH) is offering a funding opportunity titled "Formative and Pilot Intervention Research to Optimize HIV Prevention and Care Continuum Outcomes (R34 Clinical Trial Optional)." This initiative aims to support formative research and pilot-testing of interventions designed to enhance HIV prevention and treatment outcomes, particularly focusing on innovative strategies that address mental health, social determinants, and structural factors affecting HIV care. The funding opportunity is crucial for developing effective HIV testing and treatment linkage strategies, ultimately contributing to national goals in HIV management and reducing health disparities among affected populations. Eligible applicants can receive direct costs up to $225,000 per year for a project duration not exceeding three years, with applications due by January 9, 2026. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-23-060.html.
HIV Prevention and Alcohol (R34 Clinical Trials Optional)
National Institutes of Health
The National Institutes of Health (NIH) is offering a funding opportunity titled "HIV Prevention and Alcohol (R34 Clinical Trials Optional)" aimed at expanding the HIV/AIDS prevention toolkit among populations impacted by alcohol use. This grant seeks to support research that integrates effective prevention and treatment interventions while addressing the behavioral and biological risks associated with alcohol consumption, particularly among high-risk groups. The initiative is crucial for informing the design of future clinical trials focused on HIV prevention, with an anticipated funding amount of approximately $1.5 million for 2-4 awards. Interested applicants, including higher education institutions and community organizations, must submit their proposals by September 7, 2025, and can find additional information at NIH Grants or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
High Priority HIV and Substance Use Research (R01 Clinical Trial Optional)
National Institutes of Health
The National Institutes of Health (NIH) is offering a funding opportunity titled "High Priority HIV and Substance Use Research (R01 Clinical Trial Optional)" aimed at supporting innovative research at the intersection of HIV and substance use. This initiative seeks proposals that address critical gaps in understanding and improving health outcomes for individuals living with HIV who also face substance use disorders, requiring detailed research plans and preliminary data from both individual researchers and research teams. NIH plans to allocate approximately $3 million annually for three to five awards over three years, with applications due by January 11, 2025, and a strong emphasis on enhancing diverse perspectives through an inclusion plan. For further inquiries, interested applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-024.html.
HIV Prevention and Alcohol (R34 Clinical Trials Optional)
National Institutes of Health
The National Institutes of Health (NIH), through the National Institute on Alcohol Abuse and Alcoholism (NIAAA), has announced a Notice of Funding Opportunity (NOFO) titled "HIV Prevention and Alcohol (R34 Clinical Trials Optional)." This initiative aims to enhance the HIV prevention toolkit for populations affected by alcohol consumption, focusing on the integration of effective prevention and treatment interventions to reduce the incidence of new HIV infections. The program is particularly relevant for high-risk groups, including men who have sex with men, transgender individuals, and others impacted by alcohol-related HIV transmission, emphasizing the need for innovative strategies to address health disparities. The funding opportunity offers a total estimated program funding of $1.5 million for 2-4 awards, with individual project budgets capped at $450,000, and applications are due by May 7, 2026. Interested applicants can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries and should refer to the full announcement for detailed application guidelines.
Innovations to Optimize HIV Prevention and Care Continuum Outcomes (R21 Clinical Trial Optional)
National Institutes of Health
The National Institutes of Health (NIH) is inviting proposals for the R21 Exploratory/Developmental Research Grant under the funding opportunity titled "Innovations to Optimize HIV Prevention and Care Continuum Outcomes." This initiative aims to support innovative research that enhances HIV prevention and care strategies by exploring behavioral and social science approaches, new intervention methods, and implementation science, particularly addressing gaps in engagement, adherence, and retention in healthcare services. The grant, with a funding ceiling of $275,000 over two years, emphasizes collaboration with community organizations and the inclusion of diverse populations, aligning with national and global health objectives. Interested applicants can submit their proposals until January 9, 2026, and should direct inquiries to NIH Grants Information at grantsinfo@nih.gov.
Exploratory Studies to Investigate Mechanisms of HIV infection, Replication, Latency, and/or Pathogenesis in the Context of Substance Use Disorders (R01 Clinical Trial Not Allowed)
National Institutes of Health
The National Institutes of Health (NIH) is offering a funding opportunity titled "Exploratory Studies to Investigate Mechanisms of HIV infection, Replication, Latency, and/or Pathogenesis in the Context of Substance Use Disorders" through the R01 Research Project Grant. This initiative aims to support innovative and high-risk studies that explore the molecular mechanisms linking HIV and substance use disorders (SUDs), with a focus on advancing understanding of HIV dynamics within the Central Nervous System (CNS). The total estimated program funding is $2 million for fiscal year 2026, with the potential to support up to three awards, and applications must include clear milestones and human or primate studies. Interested applicants should note that the deadline for submitting letters of intent and applications is July 14, 2025, and no clinical trials are permitted under this grant. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
Pilot and Feasibility Studies in Preparation for Substance Use Prevention Trials (R34 Clinical Trial Optional)
National Institutes of Health
The National Institutes of Health (NIH) is offering a funding opportunity titled "Pilot and Feasibility Studies in Preparation for Substance Use Prevention Trials," aimed at encouraging pilot research to develop and test interventions that prevent or delay substance use. The initiative focuses on the creation and pilot testing of new or adapted strategies to curb substance misuse, particularly among underserved populations, while also addressing related negative outcomes such as impaired driving and transmission of infectious diseases. Eligible applicants include a wide range of institutions, such as academic, nonprofit, and government organizations, with funding available up to $450,000 over three years. Interested parties should note that applications are due starting January 16, 2024, and can direct inquiries to grantsinfo@nih.gov for further information.
Ex Vivo Models for Studies at the Intersection of HIV and Poly-Substance Use (R01 Clinical Trial Not Allowed)
National Institutes of Health
The National Institutes of Health (NIH) is inviting grant applications for the initiative titled "Ex Vivo Models for Studies at the Intersection of HIV and Poly-Substance Use (R01 Clinical Trial Not Allowed)." This funding opportunity aims to investigate the neuroimmune and neuronal-glial mechanisms associated with HIV-associated neurological disorders (HAND) using advanced ex vivo culturing platforms derived from human induced pluripotent stem cells (hiPSC) in the context of addictive substances. The research is critical for understanding the genetic, epigenetic, and neuroimmune interactions that contribute to HAND, particularly in the presence of substances like opioids and cocaine. The NIH has committed a total of $2 million annually for Fiscal Years 2024-2026, with applications due by 5 PM local time on August 13, 2025. Interested applicants can find more information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
Planning for Product Development Strategy (R34 Clinical Trial Not Allowed)
National Institutes of Health
The National Institutes of Health (NIH) has announced a funding opportunity titled "Planning for Product Development Strategy," aimed at supporting the development of comprehensive strategies for next-generation treatments and preventive measures for HIV and its associated complications. This grant opportunity encourages eligible applicants, including various educational institutions and community organizations, to create innovative product development plans that align with FDA guidelines, facilitating the submission of Investigational New Drug (IND) applications. With a total estimated funding of $225,000 available for individual projects, applications are due by December 5, 2026, and must adhere to specific guidelines emphasizing scientific merit and compliance. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link provided in the announcement.